Med BioGene Adopts Shareholder Rights Plan | GenomeWeb

NEW YORK (GenomeWeb News) – Canadian diagnostic developer Med BioGene announced the adoption of a shareholder rights plan.

Med BioGene said that the purpose of the rights plan is to provide sufficient time to its board and shareholders to assess any unsolicited bids to take over the company, and to allow the board to consider "value-enhancing" alternatives and entertain competing bids.

The rights plan is subject to ratification by shareholders at the company's annual meeting, to be held on Feb. 12.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.